IMF Adjusts Egypt's Growth Forecasts: 4.2% in 2023

Egyptian capital, Cairo. (Reuters)
Egyptian capital, Cairo. (Reuters)
TT

IMF Adjusts Egypt's Growth Forecasts: 4.2% in 2023

Egyptian capital, Cairo. (Reuters)
Egyptian capital, Cairo. (Reuters)

The International Monetary Fund (IMF) has updated its forecasts for Egypt's economy to 4.2% in 2023 and 3.6% in 2024.

Egypt’s economy reached 6.7% in 2022, according to the IMF in its World Economic Outlook report released in Marrakesh.

The report predicts that Egypt’s inflation will rise to 23.5% in 2023 and 32.2% in 2024.

The current account balance is projected to reach -1.7% of GDP in FY 2022/23, and -2.7% in 2024.

Additionally, the report suggests that unemployment rates in Egypt may reach this year 7.1% and rise to 7.5% next year from 7.3% in 2022.

The Fund tackles the financial year extending from July to the end of June of each year.

Egypt’s annual urban consumer price inflation rose to a historic high of 38% in September, climbing from 37.4% in August and topping analyst expectations, data from statistics agency CAPMAS showed on Tuesday.

It was the fourth consecutive month of record highs recorded on the central bank website, which has figures going back to 2000.

The median forecast of 18 analysts polled this week had shown annual urban consumer inflation rising to 37.6% in September.

The previous high, before inflation soared in June, was 32.95% recorded in July 2017.

Inflation also accelerated on a monthly basis, with prices rising by 2.0% compared with a 1.6% increase in August, Allen Sandeep of Naeem Brokerage said. It was their fastest pace of increase since June.

In September food and beverages climbed month-on-month by 3.6%, with vegetable prices surging by 19.2%, fruits by 5.4%, dairy products by 5.4%, and sugar items by 2.9%, Sandeep added.

Seeking to fight food inflation, the government said on Monday it had agreed with private producers and retailers to cut prices on staple foods by 15-25% and exempt them from customs duties for six months.

Rapid money supply growth over the last two years has helped prices to climb rapidly and the currency to lose almost half its value against the US dollar since March 2022. Many Egyptians have seen their living standards slide.



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.